Experience of Long-Term Use of Afala in Benign Prostatic Hyperplasia

The use of ultra-low doses of antibodies to the prostate-specific antigen (afala) for long-term treatment of benign prostatic hypertrophy in patients with moderately severe symptoms can quickly and effectively reduce irritative and obstructive symptoms, significantly reduce the volume of residual urine, and increase the speed of urination. Afala therapy is indicated for patients with stage I-II benign prostatic hyperplasia with moderately severe symptoms.